NW FiPS 10II.3-R4F-1

General

Cell Line

hPSCreg name ESi100-A
Cite as:
ESi100-A (RRID:CVCL_A7HK)
Alternative name(s)
NW FiPS 10II.3-R4F-1
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
ESi060-A
([SWB] FiPS-4F-5-6)
Donor diseases:
Williams syndrome
UMILi021-A
(WBS03)
Donor diseases:
Williams-Beuren syndrome
UMILi023-A
(WBS02)
Donor diseases:
Williams-Beuren syndrome
ESi059-B
([SWB] FiPS1-R4F-5)
Donor diseases:
Williams syndrome
ESi060-B
([SWB] FiPS5-R4F-1)
Donor diseases:
Williams syndrome
ESi068-A
(SWB FiPS 159-R4F-4)
Donor diseases:
Williams-Beuren syndrome
UMILi020-A
(WBS04)
Donor diseases:
Williams-Beuren syndrome
ESi069-A
(SWB FiPS 344-R4F-2)
Donor diseases:
Williams-Beuren syndrome
UMILi022-A
(WBS01)
Donor diseases:
Williams-Beuren syndrome
ESi059-A
([SWB] FiPS-4F-1-1)
Donor diseases:
Williams syndrome
NMIi004-A
Donor diseases:
Schizophrenia
NMIi006-A
Donor diseases:
Schizophrenia
NMIi006-B
Donor diseases:
Schizophrenia
UKBi007-A
(LB-33-5, iLB-MJD3-33f-r5)
Donor's gene variants:
ATXN3, ATXN3
Donor diseases:
Spinocerebellar ataxia type 3
CSSi003-A
(COL04 clE2)
Donor diseases:
Smith-Magenis syndrome
UKBi001-B
Donor's gene variants:
ATXN3
Donor diseases:
Spinocerebellar ataxia type 3
UNEWi022-A
(F181 5.8)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi024-A
(F180-1)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
NMIi002-A
Donor diseases:
Schizophrenia
UNEWi022-B
(F181 18.2)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi022-C
(F181 25.7)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi026-A
(SF116 clone 1)
Donor's gene variants:
CFH
Donor diseases:
type 2 diabetes mellitus
age-related macular degeneration
NMIi005-A
Donor diseases:
Schizophrenia
UNEWi024-B
(F180-2)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
UNEWi024-C
(F180-3)
Donor's gene variants:
CFH
Donor diseases:
age-related macular degeneration
NMIi002-B
Donor diseases:
Schizophrenia
UNEWi026-B
(SF116 clone 2)
Donor's gene variants:
CFH
Donor diseases:
type 2 diabetes mellitus
age-related macular degeneration
UNEWi026-C
(SF116 clone K)
Donor's gene variants:
CFH
Donor diseases:
type 2 diabetes mellitus
age-related macular degeneration
UCLi006-A
(LCMD-L302P-UCL01C2)
Donor's gene variants:
LMNA
Donor diseases:
Congenital muscular dystrophy due to LMNA mutation
UKBi003-A
(iLB-MJD1-32m-r9, LB-32-r9)
Donor's gene variants:
ATXN3, ATXN3
Donor diseases:
Spinocerebellar ataxia type 3
UKBi008-A
(iLB-MJD4-34m-r1, LB-34-1)
Donor's gene variants:
ATXN3, ATXN3
Donor diseases:
Spinocerebellar ataxia type 3
Last update 13th April 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Spanish Stem Cell Bank (ES)
Owner Spanish Stem Cell Bank (ES)
Distributors
Derivation country Spain

External Databases

BioSamples SAMEA112641362
Cellosaurus CVCL_A7HK
Wikidata Q107116600

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 40-44

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Atypical deletion of the 7q11.23 Williams-Beuren Syndrome Region
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Williams Syndrome
  • Williams-Beuren Syndrome (WBS)
  • Williams-Beuren Syndrome
  • Williams syndrome
show more synonyms
Is the medical history available upon request? no
Is clinical information available? no

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA112641311

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Characterization of 7q11.23 reciprocal aneusomy syndromes: from patients to functional pathways (and back)
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? No
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Institution
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Clinical Research Ethics Committee of the Regenerative Medicine Center of Barcelona
Approval number 347 290 1
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Clinical Research Ethics Committee of the Regenerative Medicine Center of Barcelona
Approval number 347 290 1
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Any skin fibroblast that is part of some dermis.
Source cell origin
Age of donor (at collection) 40-44
Collected in 2016
Passage number reprogrammed 4

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
Yes
Reprogramming vectors silenced?
Yes
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones good morphology and integration and silencing of reprogramming vectors
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Unknown

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
SOX2
Yes
TRA 1-60
Yes
TRA 1-81
Yes
SSEA-3
Yes
SSEA-4
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro directed differentiation
Marker Expressed
AFP
Yes
FOXA2
Yes
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro directed differentiation
Marker Expressed
ASA
Yes
ASMA
Yes
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro directed differentiation
Marker Expressed
Tuj1
Yes
GFAP
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX
Passage number: 14
Karyotyping method: G-Banding

Other Genotyping (Cell Line)